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Introduction: Timing of medical delivery of preterm newborns exposed to placental
insufficiency is largely determined by umbilical artery blood flow and maternal clinical
manifestations. There is a lack of tools to properly assess fetal body response to placental
insufficiency before or upon delivery. Yet, short- and long-term comorbidities associated
with placental insufficiency and the consequential intrauterine growth restriction may
be a result of fetal response following prolonged stress. This study aims to establish a
procedure to investigate fetal/neonatal transcriptional response to placental insufficiency
as part of an initiative to identify cost-effective biomarkers for assessing fetal response
to placental insufficiency.
Methods: A prospective pilot study involving newborns with birth gestation <32 weeks
was conducted to compare gene expression profiles in whole blood collected at birth
among three clinically distinct groups - preeclampsia without placental insufficiency (PE),
placental insufficiency (PI), and non-PE/PI groups.
Results: Whole blood from 11, 3, and 6 newborns in the non-PE/PI, PE, and PI
groups were obtained. A transcriptome analysis found that the majority of the genes
were downregulated in the PI group, suggesting global transcriptional inactivation.
Intriguingly, SLC25A42, which encodes a mitochondrial transporter for coenzyme A and
adenosine-3′ ,5′ -diphosphate, was significantly upregulated in the PI group.
Conclusion: Transcriptional biomarkers for assessing fetal response to placental
insufficiency may provide a useful tool to better understand the pathophysiology of
fetal reprogramming in response to placental insufficiency. The validity and the role of
SLC25A42, as well as its correlation with short- and long-term neonatal outcomes,
warrants further investigation.
Keywords: placental insufficiency, transcriptional biomarkers, intrauterine growth restriction, transcriptome
analysis, fetal reprogramming
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INTRODUCTION

Kansas Medical Center (KUMC) and the Office of Research
Integrity at Children’s Mercy-Kansas City. Pregnant women
admitted to the Labor & Delivery unit at KUMC for threatened
preterm delivery at <32 weeks gestation were screened for
study participation. Informed consent for collecting neonatal
blood upon delivery as well as maternal and neonatal clinical
information was obtained after all questions were answered.
Criteria for participation included delivery at <32 weeks
gestation, singleton or dichorionic-diamniotic twin. Newborns
were excluded if multiple congenital anomalies or congenital
cytomegalovirus infection was diagnosed. Based on the absence
or presence of maternal preeclampsia and placental insufficiency,
E/VPNs were assigned to one of the three groups for comparison:
[1] no maternal preeclampsia or placental insufficiency (the
non-PE/PI group); [2] maternal preeclampsia but no placental
insufficiency (the PE group); and [3] placental insufficiency
(the PI group). Maternal preeclampsia diagnosis was based on
maternal chart review, and placental insufficiency in this study
was defined as abnormal UA blood flow, including a pulsatility
index of >95%, absent end-diastolic flow, or reversed enddiastolic flow (8, 10). The grouping strategy was based solely
on chart review of maternal diagnosis and the most recent
umbilical Doppler findings prior to delivery without further
considering underlying etiologies (e.g., TORCH infections,
maternal smoking, pre-existing maternal hypertension, etc.).
The indications for preterm delivery of E/VPNs in the nonPE/PI group were variable, mostly due to premature rupture of
membrane or placental abruption.

Survival of extremely preterm newborns (EPNs, those that
are born at 27 weeks gestation or less) and very preterm
newborns (VPNs, those that are born between 28 and
31 weeks) have increased significantly in the past decade
due to substantial improvement in clinical management and
technology (1). Surviving E/VPNs are at increased risk
for neurodevelopmental abnormalities, including cognitive
impairment, learning disabilities, and mental health issues (2–4).
Those E/VPNs who experienced intrauterine growth restriction
(IUGR) are at even greater risk of adverse neurodevelopmental
outcomes and cardiometabolic derangement (5, 6). IUGR has
also been shown to cause a multitude of short- and long-term
complications involving almost all organ systems (7).
The etiologies of IUGR can be categorized into maternal,
fetal, and placental. Placental vasculopathy is considered one
of the most common causes of IUGR. Placental vasculopathy
causes maternal preeclampsia and eclampsia, and is associated
with placental insufficiency, a condition where blood supply
toward the growing fetus is compromised, resulting in chronic
fetal hypoxia and nutrient deprivation. Prolonged placental
insufficiency results in fetal reprogramming to ensure
conservation of energy in the growing fetus. As a result,
IUGR ensues. Fetal reprogramming may serve as the molecular
basis of the short- and long-term complications of IUGR,
yet the molecular and cellular mechanisms underlying fetal
reprogramming remains largely unexplored. The current
standard of practice for diagnosing placental insufficiency is
based on detection of abnormal umbilical artery blood flow,
including a pulsatility index higher than 95%, or the presence of
absent or reverse end-diastolic flow (8). The diagnosis of IUGR
by fetal weight estimation using non-invasive sonography is
still a challenge, and the presence of IUGR may indicate that
irreversible fetal reprogramming has already occurred (9).
Limitations in sonographic detection of placental insufficiency
include the need for an experienced sonographer and relatively
high cost; sonographic studies are also not always readily
available to pregnant women who are at risk. More importantly,
the tools for diagnosing placental insufficiency does not provide
information with regard to fetal response to the intrauterine
stress to guide clinical decision making in terms of delivery of the
fetus vs. expectant management. Alternatively, transcriptional
biomarkers for assessing global and/or targeted fetal gene
regulation in response to placental insufficiency may be an
ideal tool to determine whether fetal stress and reprogramming
are present, and to what extent. In order to achieve this
ultimate goal, we took an initiative and conducted a pilot study
to establish a procedure for correlating fetal/neonatal whole
blood transcriptome with placental insufficiency. We hypothesize
that transcriptome profiles are altered in response to placental
insufficiency-induced intrauterine stress in the growing fetuses.

Blood Collection and Processing
One-half milliliter of whole blood was collected during umbilical
catheter placement, typically within 1 h of birth. Blood was

TABLE 1 | Maternal and neonatal characteristics.
Group

Number

No maternal
Maternal
preeclampsia/placental preeclampsia
insufficiency
(PE)
(Non-PE/PI)
11

Placental
insufficiency
(PI)

3

6

MATERNAL CHARACTERISTICS
Maternal age (year)

29.5 ± 7.5

30.7 ± 2.9

29 ± 6.4

Non-Hispanic
white (n)

10

3

4

Hispanic white (n)

0

0

1

Black (n)

1

0

1

NEONATAL CHARACTERISTICS
Female (n)
Gestational age at
birth (week)
Birth weight (g)

9

2

2

27.5 ± 2.9

28.3 ± 3.2

27.4 ± 2.3

1.125 ± 387

1.099 ± 325

836 ± 358

0.3 ± 0.7

0 ± 0.6

−1.2 ± 0.7

METHODS

Birth weight
z-score

Study Subjects

Median APGAR at
1 min

7

3

5

The study was approved by Institutional Review Board of
the Human Research Protection Program at the University of

Median APGAR at
5 min

8

7

8
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facility. Sequencing raw data has been deposited in GenBank
(BioProject: PRJNA639860). Raw counts were downloaded in
the fastq file format for quasi-mapping using Salmon (11).
The Genome Reference Consortium Human Build 38 version
was used as reference. The differential gene expression analysis
was performed in R (version 3.6.1) and the RStudio (version
1.2) integrated development environment using the DESeq2
package (12).

collected into a non-additive specimen tube and placed in
a −20◦ C freezer within 30 min of collection. For RNA
extraction, TRIzolTM (ThermoFisher Scientific, Waltham, MA,
USA) was added directly to the frozen blood specimen following
manufacturer’s instructions. RNA concentration was measured
using a Qubit fluorometer (ThermoFisher Scientific). For all
samples, handling of RNA was performed by the same person
in order to minimize variation introduced by sample processing.
RNA was then stored in a −80◦ C freezer until use.

RESULTS
RNA Sequencing and Transcriptome
Analysis

Patient Characteristics
A total of 20 whole blood samples were collected, including
11 for the non-PE/PI group, 3 for the PE group, and 6 for
the PI group. Patient characteristics are listed in the Table 1.
No significant differences in the mean maternal age and the
mean gestational age at birth were observed. As expected, the
PI group had the lowest mean birth weight and mean birth
weight z-score when compared to the non-PE/PI and the PE
groups. The median 1 min APGAR score was lower in the
PE and the PI groups, indicating higher likelihood of needing

RNA sequencing (paired-end 75 base pair sequences with
a sequencing depth of 25 million reads per sample) was
performed by using an Illumina NextSeq sequencer at the
Oklahoma State University Genomics facility. RNA integrity was
checked by using the Agilent 2200 TapeStation system (Agilent,
Santa Clara, CA) prior to sequencing. Post-sequencing data
processing, including demultiplexing, file format conversion,
and quality trimming were also performed by the sequencing

FIGURE 1 | Volcano plots showing pairwise comparisons of gene expression between the non-maternal preeclampsia/placental insufficiency (non-PE/PI) and the PE
groups (A), as well as between the non-PE/PI and the PI groups (B).
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resuscitation in the delivery room among E/VPNs born to
mothers with preeclampsia or placental insufficiency. However,
median APGAR score at 5 min of life was comparable among all
three groups.

findings from a pilot study aiming to establish a process for
identifying transcriptional biomarkers for use in assessing fetal
response to placental insufficiency. The long-term goal is to
develop useful biomarkers to better examine fetal stress and
reprogramming in response to placental insufficiency at its early
stage before IUGR becomes detectable by conventional imaging
studies, and to assist clinicians in determining the most optimal
timing for delivery in order to prevent long-term comorbidities
from IUGR.
In this pilot study, we showed that the process of blood
collection from E/VPNs for RNA extraction, sequencing, and the
subsequent transcriptome analysis for candidate transcriptional
biomarker identification is feasible. We chose to collect
circulating blood from the E/VPNs rather than from the
umbilical cord due to logistic reasons (i.e., lack of easy access to
placenta and umbilical cords after delivery) as well as the routine
practice of delayed cord clamping during the delivery process
in this population, which has been shown to improve shortand long-term outcomes (13). Moreover, blood collected upon
umbilical catheter placement prior to fluid infusion were thought
to contain cell types that are adequate for assessing fetal response
to the intrauterine stress. As there was no additional physical
stress associated with blood collection, we experienced no
procedure-related complications in our small cohort. Although
interventions provided to the newborns during delivery room
resuscitation may potentially cause changes in gene expression, it
was unlikely to occur, as we were able to collect and freeze whole
blood within the first 1–2 h of life.
Several studies have successfully identified candidate
biomarkers (metabolites or epigenetic alterations) from bodily
fluids during pregnancy or upon delivery for correlation
with pregnancy complications and the well-being of the
offspring (14, 15). Transcriptome profiling with the use of
RNA sequencing technology has emerged as a mainstream
methodology in studying biological activities during normal
development and functioning, as well as molecular responses to
disturbances in biological homeostasis. It provides insights into
how organisms react and adapt to changes in the environment
at the cellular and molecular levels, and the signaling pathways
involved (16). A recent landmark paper by Ngo et al. described
the use of transcriptome profiles of maternal cell-free RNA
derived from fetal tissues in combination with machine learning
algorithms to identify candidate transcriptional biomarkers for
preterm birth (17). In a similar manner, candidate transcriptional
biomarkers short-listed from the current study or from future
endeavor with a larger cohort may be further validated in fetal
tissue-derived cell-free RNA in maternal blood prior to birth to
quantify fetal response at the first sign of placental insufficiency,
or even as a routine screening test in the high-risk population.
Additionally, with its simplicity, serial blood testing may be
performed on the at-risk pregnant women to closely trend fetal
response to placental insufficiency.
Little is known about the role of SLC25A42 in response
to the chronic hypoxia and nutrient deprivation associated
with placental insufficiency. As the name implies, SLC25A42
is a member of the solute carrier family which serves as a
transporter for Coenzyme A and adenosine 3′ ,5′ -diphosphate

Transcriptome Analysis
In volcano plots, we found that the majority of genes in the PI
group were downregulated when compared to the non-PE/PI
group; on the other hand, the numbers of the genes that were
upregulated and downregulated were comparable between the
non-PE/PI and the PE groups (Figure 1).
Mapped sequences were called by DESeq2 for differential
gene expression (DGE) analysis. The DESeq2 package applied a
negative binomial statistical approach and utilized raw counts
for DGE analysis (12). To identify candidate biomarkers for
placental insufficiency, we searched for genes that were not
differentially expressed between the non-PE/PI and the PE
groups but were differentially expressed between the non-PE/PI
and the PI groups. We found that SLC25A42, a gene that encodes
a mitochondrial transporter for Coenzyme A and adenosine3′ ,5′ -diphosphate, was significantly upregulated in the PI group
when compared to the other two groups (Figure 2).

DISCUSSION
Placental insufficiency is a common pregnancy complication
which may lead to IUGR as well as multi-system short- and
long-term adverse outcomes in the offspring. This report detailed

FIGURE 2 | Comparison of SLC25A42 gene expression levels among
non-maternal preeclampsia/placental insufficiency (non-PE/PI), maternal
preeclampsia (PE), and the placental insufficiency (PI) groups.
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robust to detect transcripts expressed at very low copy numbers.
Overall, precautions must be taken when interpreting findings
from this pilot study.
In conclusion, fetal transcriptional biomarkers may be a
useful tool for assessing fetal response to placental insufficiency.
Analysis of transcriptional alterations may also provide insight
into the molecular basis of fetal reprogramming and the signaling
pathways involved. A larger prospective study with clinical
correlation, especially the long-term well-beings of the V/EPNs,
is needed.

in human mitochondria, suggesting that it plays a role in
energy production and utilization (18). The significance of its
upregulation in the context of placental insufficiency remains
elusive and may warrant further molecular studies. Additionally,
it would be interesting to correlate SLC25A42 expression levels
with long-term outcomes of neonates in future studies. It is
essential to emphasize that, because of the small cohort size
in this feasibility study, the role of SLC25A42 as a potential
transcriptional biomarker for placental insufficiency requires
further confirmation with a larger study.
The timing of delivery in pregnancies complicated by
preeclampsia or placental insufficiency is controversial, especially
when the clinical issue develops at a gestational age that does not
imply favorable neonatal outcomes. The detection of IUGR may
play a role in clinical decision making, as it indicates ongoing
and prolonged intrauterine stress. However, in such case,
fetal reprogramming likely has already occurred, and therefore
the associated short-term and long-term adverse outcomes
(e.g., neurodevelopmental abnormalities and cardiometabolic
risks) may have already become irreversible. Indeed, a recent
study suggested that exposure to placental insufficiency by
itself was sufficient to significantly alter postnatal growth
trajectories, likely due to fetal reprogramming (10). Therefore,
it is very likely that the developmental trajectory of the fetus
is already altered and compromised when IUGR becomes
detectable clinically. On the other hand, detection of placental
insufficiency by Doppler studies without adequate assessment
of fetal response may potentially lead to unnecessary premature
delivery of fetuses that are not compromised. When cost-effect
biomarkers for assessing fetal response to placental insufficiency
become available for clinical use, it may be reasonable
to take fetal response into consideration when determining
the best timing for medical delivery of fetuses exposed to
placental insufficiency.
Limitations of the study included a small sample size in
each group and the heterogeneous nature of the non-PE/PI
group without proper statistical adjustment due to small sample
size. It also needs to be emphasized that the non-PE/PI group,
although treated as the reference group for comparison in
this pilot study, is not a conventional “control” group, as
all preterm deliveries occur for a reason, which may have
altered transcriptional regulations in different ways. The study
was based on an assumption that a subset of transcripts was
uniquely regulated in response to PE and/or PI. The study
also did not take gender differences into consideration. Gender
disparities in fetal response to IUGR has been well-established
and must be addressed in future large-scale studies (19). Blood
collected during umbilical catheter placement, albeit simple,
contains a heterogenous population of nucleated cells and may
confound biomarker identification. The most optimal site for
blood sampling for RNA extraction is related to clinical questions
to be solved, and blood samples collected from various sites
may be further compared in future studies. From the sequencing
standpoint, sequencing depth in this study may not be sufficiently
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